主要目的：评价在空腹状态下，单次皮下注射0.25mg试验药（T）司美格鲁肽注射液（宜昌人福药业有限责任公司提供，规格：1.34mg/ml，1.5ml）与0.25mg参照药（R）司美格鲁肽注射液（Novo Nordisk A/S生产，商品名：诺和泰，规格：1.34 mg/ mL，1.5 ml）在健康成年受试者体内的药代动力学特征的相似性。次要目的：评价试验药司美格鲁肽注射液与参照药（诺和泰）在健康成年受试者中的免疫原性与安全性。

开始日期2024-11-29

申办/合作机构

海南双成药业股份有限公司

[+1]

100 项与司美格鲁肽(宜昌人福药业) 相关的临床结果

登录后查看更多信息

100 项与司美格鲁肽(宜昌人福药业) 相关的转化医学

登录后查看更多信息

100 项与司美格鲁肽(宜昌人福药业) 相关的专利（医药）

登录后查看更多信息

167

项与司美格鲁肽(宜昌人福药业) 相关的文献（医药）

2026-02-01·PHARMACOLOGICAL RESEARCH

A gut-liver lipid flux checkpoint mediates FAHFA protection from MASLD

Article

作者: Tan, Soon Heng ; Zhang, Shuang ; Xie, Hao ; Cheng, Hong Sheng ; Tan, Choon-Hong ; Tan, Nguan Soon ; Kim, Joseph Han Sol ; Ng, Jia Xun Jarryl

Pharmacotherapies for metabolic dysfunction-associated steatotic liver disease (MASLD) remain limited. Although resmetirom and semaglutide have approvals for MASH, gut-liver axis options are still needed. Fatty Acid Esters of Hydroxy Fatty Acids (FAHFAs) offer anti-inflammatory and metabolic benefits but are constrained by poor stability and synthesis complexity. We develop a modular, scalable chemistry platform that installs bioisosteric linkages to generate orally stable, gut-retentive FAHFAs. High-throughput screening identifies lead candidates (12-TAASA, 12-HDTZSA) that selectively inhibit intestinal lipid handling while sparing glucose absorption. In a diet-induced MASLD model, oral dosing reduces weight gain, lowers hepatic triglycerides, improves steatosis histology and liver injury markers, and enhances glycemic control, achieving efficacy comparable to semaglutide. Mechanistically, we identify an intestine-anchored dual-brake mechanism. First, 12-TAASA slows and diminishes gut-to-liver lipid flux in vivo, directly reducing the dietary lipid burden reaching the liver. Second, 12-TAASA and 12-HDTZSA remodel the gut microbiome toward short-chain fatty acid (SCFA)-producing consortia and increase circulating, bacterially derived SCFAs, providing a complementary, microbiota-mediated route to systemic metabolic benefit. Multi-omics integration further implicates a CD44-centered epithelial program, together with allied lipid-handling pathways, as a key intestinal target network governing flux control. These findings position stabilized FAHFAs as gut-localized agents that couple epithelial lipid-uptake restraint with microbiome-derived SCFA signals to reduce gut-to-liver lipid flux, establishing an orally active, dual-action strategy for MASLD.

2026-02-01·Clinical Obesity

Treatment Approaches for Obesity in Children With Heterozygous MC4R Variants

Article

作者: Valdez, Lourdes ; Lteif, Aida ; Kumar, Seema ; Salama, Mostafa ; Saba, Leslie

ABSTRACT:

Melanocortin‐4 receptor (MC4R) deficiency is the most common cause of monogenic obesity; yet treatment options for children with MC4R mutations are limited. We describe significant improvement in weight in three patients with pathogenic or likely pathogenic MC4R mutations; two adolescents treated with semaglutide, and a younger child treated with metformin and topiramate. These findings indicate GLP‐1 receptor agonists, topiramate and metformin can be helpful in managing obesity associated with MC4R deficiency.

2026-01-01·DIABETES-METABOLISM RESEARCH AND REVIEWS

Effectiveness of GLP‐1 RAs in Restoring Normoglycemia in Patients With Prediabetes: An Updated Systematic Review and Meta‐Analysis

Review

作者: Tsolaki, Vasiliki ; Antonogiannis, Thomas ; Bargiota, Alexandra ; Zakynthinos, George ; Tsironikos, Georgios I. ; Zakynthinos, Epameinondas ; Rammou, Vasiliki ; Kyprianidou, Despoina

ABSTRACT:

Background:

Glucagon‐like peptide 1 receptor agonists (GLP‐1‐RAs) effectiveness in normalising prediabetes has been evaluated in recent randomised control trials (RCTs), but the data has not been synthesised to guide everyday clinical management.

Objective:

To perform an updated Systematic Review (SR) and Meta‐Analysis (MAs) for GLP‐1 RAs' effectiveness in reversing prediabetes to normoglycemia and assess their action in clinical practice.

Material and Methods:

Search for eligible RCTs in PubMed and Cochrane Library Central Register of Controlled Trials. A SR and MA with special emphasis on studies' and participants' characteristics. GRADE assessment of overall evidence.

Results:

All 14,564 participants in 8 RCTs had obesity disease additionally to prediabetes. GLP‐1 RAs restored normoglycemia compared to placebo (OR 4.62, 95% CI 2.85, 7.49; p ‐value < 0.00001). Both semaglutide (OR 4.87, 95% CI 2.61, 9.09; p ‐value < 0.00001) and liraglutide (OR 5.43, 95% CI 1.34, 22.04; p ‐value 0.02) were effective but not exenatide. The assessed semaglutide's weekly dosage of 2.4 mg (mg) was effective and significance concerns studies performed across the world without post‐intervention duration, and independent of cardiovascular disease (CVD). Either 1.8 mg or 3.0 mg of liraglutide daily is effective and 3.0 mg maintains post‐intervention effectiveness. Semaglutide was more effective in men and liraglutide in women. They are both effective independent of patients' mean age, and intervention's duration. Heterogeneity was large (Q 84.42, p ‐value < 0.00001; I2 92%, 95% CI 77, 97%), attributed to the countries' performance and post‐intervention follow‐up in semaglutide‐based RCTs and any subgroup analysis in liraglutide‐based RCTs. The overall quality of evidence was low.

Conclusions:

Semaglutide and liraglutide may reverse prediabetes to normoglycemia in patients with prediabetes and obesity disease. Further research is needed for normal‐weight patients with prediabetes, for semaglutide's post‐intervention effect, and for liraglutide in men.

项与司美格鲁肽(宜昌人福药业) 相关的新闻（医药）

2026-01-05

·drugs

GLP-1 Drugs Might Help Quell Sleep Apnea

MONDAY, Jan. 5, 2026 — A good night’s sleep might be an additional benefit some gain from taking weight-loss drugs like Ozempic and Zepbound , a new study says. Obese patients with type 2 diabetes are less likely to need a CPAP machine to treat sleep apnea if they’re taking a GLP-1 drug, researchers recently reported in JAMA Network Open . Patients were also less likely to die or require hospitalization when taking GLP-1 drugs, the study found. “These findings align with recent randomized clinical trials showing that (GLP-1 drugs), especially tirzepatide, improved obstructive sleep apnea severity, potentially through weight loss and metabolic or respiratory mechanisms,” wrote the team led by senior researcher Yong Chen , a professor of biostatistics at the University of Pennsylvania’s Perelman School of Medicine in Philadelphia. Sleep apnea occurs when the muscles in the back of the throat relax, causing a person’s airway to collapse. These folks tend to snore and if the airway collapses completely, their breathing can start and stop throughout the night, causing them to repeatedly wake. Continuous positive airway pressure (CPAP) machines blow air through a face mask as a person sleeps. The air pressure prevents the person’s airways from closing. For the study, researchers analyzed the medical records of more than 93,000 people with obesity, type 2 diabetes and sleep apnea who had been prescribed a GLP-1 drug. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. The most well-known are semaglutide ( Ozempic , Wegovy) and tirzepatide (Mounjaro, Zepbound). The research team compared the outcomes of patients on GLP-1 drugs against those taking another type of diabetes drug called sodium-glucose cotransporter-2 inhibitors, or SGLT2Is. After an average follow-up of nearly a year, people taking GLP-1 drugs were 8% less likely to need a CPAP machine to help treat their sleep apnea, results showed. They also were 32% less likely to die from any cause, and 10% less likely to be hospitalized. "This study is supportive of what we're all experiencing” when it comes to GLP-1 drugs, Dr. Gary Wohlberg , director of Northwell Health’s South Shore University Hospital Sleep Lab, said in a news release. “They're helping patients in a number of ways with health,” said Wohlberg, who was not involved in the study. “Weight loss helps with diabetes. It may help in cardiac disease, and there's a possibility that there's a more direct effect on the airway. We still need to have CPAP as our first line, but this is supportive of what we're experiencing.” GLP-1 drugs probably help people’s sleep apnea by helping them lose fat, Wohlberg said. “When you have a lot of fatty tissue and it's pretty much everywhere, it narrows vessels and airways. The airway becomes more collapsible,” Wohlberg said. “When I'm talking to patients, I principally say, ‘Look. You have a lot of fatty tissues. Your airway is also lined with that extra fatty tissue, and therefore it is more easily collapsed when the muscles that hold the airway open go to sleep when you go to sleep.’ " People also might help avoid sleep apnea by changing their sleeping position, he added. “Sleep apnea is generally worse if you're in the supine position with your mouth up because your jaw and your tongue will drop back and do the occlusion,” Wohlberg said. “Rather than sleeping flat on your back, you can be propped up a little bit or sleep on your side." Sources JAMA Network Open, Dec. 22, 2025 Northwell Health, news release, Dec. 22, 2025

临床结果

2025-12-27

·国际糖尿病idiabetes

三高共管“破局”之道：司美格鲁肽如何实现“一石三鸟”的协同效应？

点击“蓝字”关注我们引言高血糖（以2型糖尿病为代表）、高血压、血脂异常（即“三高”）是动脉粥样硬化性心血管疾病（ASCVD）发生发展的三大核心代谢性危险因素。在临床实践中，三者常常相互交织、协同作恶，形成复杂的代谢综合征，显著增加心肌梗死、卒中及心血管死亡风险。对于糖尿病管理而言，如果能在实现强效降糖这一核心目标（“一鸟”）的同时，还能够明确带来降低血压（“二鸟”）和改善血脂谱（“三鸟”）的额外获益，是不是就会“如虎添翼”，极大改善糖尿病患者的心血管结局？多项研究进展给了我们答案！本期将由保定市高阳县第三医院（邢家南镇卫生院）的刘亚辉主治医师系统阐述胰高糖素样肽-1受体激动剂（GLP-1RA）司美格鲁肽实现“一石三鸟”协同效应的临床证据与潜在机制，并探讨其在简化三高共管策略、提升治疗效率方面的革命性意义。一、第一“鸟”：强效与安全的血糖控制基石司美格鲁肽作为GLP-1RA，其降糖作用是其所有获益的基石。通过模拟人体天然GLP-1，它以葡萄糖浓度依赖性的方式，精准地促进胰岛素分泌并抑制胰高糖素分泌，抑制食欲与摄食、增加能量消耗、同时延缓胃排空[1]。这一独特机制使其在强效降糖的同时，显著降低了低血糖风险。大规模的SUSTAIN系列临床研究为司美格鲁肽强效降糖提供了坚实的数据。汇总分析显示，与安慰剂或多种活性对照药物（如西格列汀、艾塞那肽缓释剂、甘精胰岛素等）相比，司美格鲁肽（每周一次皮下注射）能显著降低糖化血红蛋白（HbA1c）1.5%~1.8%（图1），并使高达70%以上的患者实现血糖达标（HbA1c<7.0%）[2,3]。例如，SUSTAIN 3研究中，司美格鲁肽的HbA1c降幅显著优于艾塞那肽缓释剂（-1.5% vs. -0.9%）[4]；SUSTAIN China研究[5]显示，在中国2型糖尿病患者中，司美格鲁肽显著降低HbA1c水平1.8%，HbA1c的达标率高达86.1%；进一步研究分析发现，司美格鲁肽显著改善2型糖尿病患者的胰岛功能，无论患者是高基线HbA1c还是接近于7.0%，患者的β细胞应答水平可类似健康人水平，按需降低HbA1c，使其降至7.0%以内。这一强大而平稳的降糖效果，为后续的综合代谢获益奠定了坚实基础。图1. SUSTAIN 1~7研究中，司美格鲁肽相比对照药物对HbA1c较基线平均变化的影响二、第二“鸟”：明确且持续的血压下降高血压是糖尿病患者最常见、危害最大的共病之一。令人瞩目的是，司美格鲁肽在多项临床试验中表现出明确的降压效果。对SUSTAIN系列研究的汇总分析显示，接受司美格鲁肽治疗的患者，其收缩压（SBP）可出现具有统计学意义和临床意义的下降（表1），平均降低约2~6 mmHg[2]。在SUSTAIN 6心血管结局试验中，与安慰剂组相比，司美格鲁肽0.5 mg和1.0 mg组患者的收缩压平均降低了1.3 mmHg（P=0.10）和2.6 mmHg（P<0.001）[6]；在SUStAIN 5研究中，司美格鲁肽使收缩压降低高达7.3 mmHg[7]。这种降压作用意义重大，尤其是在已使用常规降压药的背景下实现的额外获益。表1. SUSTAIN 1~7研究中，HbA1c、体重、血压和血脂谱较基线的变化情况以及达到目标值的患者比例司美格鲁肽的降压作用是多途径协同的结果[8,9]，包括：①促进钠盐排泄与利尿： GLP-1受体分布于肾脏，其激活可抑制肾小管钠氢交换体（NHE3），增加尿钠排泄，从而降低血容量和血压；②改善内皮功能与血管舒张：通过增加一氧化氮的生成和生物利用度，促进血管舒张，降低外周血管阻力；③调节交感神经系统：作用于自主神经调节中枢，减少中枢交感神经输出、增强副交感神经张力，直接降低收缩压和舒张压；通过外周通路协同调节自主神经功能；④体重减轻带来的连锁效应：显著的体重减轻本身就有助于降低血压。图2. GLP-1RA独立于减轻体重的潜在降压机制[9] 三、第三“鸟”：全面改善血脂谱血脂异常是糖尿病大血管病变的另一关键推手。司美格鲁肽对血脂谱的改善作用，使其在代谢调控上更具全面性。在SUSTAIN 1~5和7研究中，与安慰剂及活性对照药物相比，司美格鲁肽0.5 mg和1.0 mg治疗导致总胆固醇、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）及甘油三酯水平相似或显著改善（表1）[2]。SUSTAIN 6研究数据显示，与基线水平相比，皮下注射司美格鲁肽可使2型糖尿病患者的甘油三酯降低7%~8%，低密度脂蛋白胆固醇（LDL-C）和总胆固醇分别降低2%[10]。司美格鲁肽通过多种机制改善血脂谱[11,12]，包括：①调节脂质代谢：激活GLP-1受体，抑制肝脏脂质代谢的关键酶，减少甘油三酯和VLDL的生成；同时，促进脂质代谢酶的表达，加速脂质分解和转运，降低血液中脂质含量。需注意的是，GLP -1 RA还通过抑制HMG-CoA还原酶和固醇调控元件结合蛋白1c（SREBP -1C）来调节胆固醇代谢，类似于他汀类药物的作用[13]。②通过改善胰岛素抵抗和调节肠道激素分泌，间接影响血脂代谢；③体重减轻的协同作用。四、协同效应与“单一路径，多重获益”的破局价值司美格鲁肽的“一石三鸟”效应并非三个孤立作用的简单叠加，而是源于其作用于GLP-1受体这一“单一路径”后，触发的系统性、网络化代谢改善。 1. 机制上的协同与联动减重是核心交汇点：司美格鲁肽通过中枢抑制食欲、延缓胃排空，带来显著且持续的体重下降（SUSTAIN系列研究平均减重4~6 kg）[2]。体重减轻可直接改善胰岛素敏感性、降低血压、减少内脏脂肪并改善肝脏脂肪代谢，从而对血糖、血压、血脂产生“一荣俱荣”的联动改善。抗炎与改善内皮功能是共同通路：司美格鲁肽被证实具有抗炎、抗氧化应激、改善内皮功能的作用。这些作用贯穿于动脉粥样硬化发展的全过程，是同时保护血管、改善血压和代谢紊乱的共享生物学基础。 2. 临床管理的革命性简化对SUSTAIN 1~5、7~10和SUSTAIN China研究的事后汇总分析数据[14]显示，在2型糖尿病患者中，一周一次皮下注射司美格鲁肽0.5 mg和1.0 mg达到复合代谢终点（定义为HbA1c<7.0%、血压<140/90 mmHg及非高密度脂蛋白胆固醇<130 mg/dl[<3.37 mmol/L]）的比例显著高于对照组（23.7%和32.0% vs. 11.5%，P值均<0.0001）（图3）。汇总剂量分析依然如此（29.1% vs. 11.4%，P<0.0001）。图3. 达到复合代谢终点或贡献性目标的受试者比例[13] 传统三高管理如同“叠加用药”，而司美格鲁肽提供了一种“源头干预”的新范式。每周一次的单一药物注射，即可同时撬动血糖、血压、血脂、体重四大关键靶点。这极大简化了治疗方案，减少了患者每日服用药物的数量和种类，降低了药物相互作用风险，并有望显著提升长期治疗依从性。 3. 心肾结局的终极获益这种多危险因素的协同管理，最终转化为硬终点结局的改善。具有里程碑意义的SUSTAIN 6研究证实，在标准治疗基础上，司美格鲁肽可将主要不良心血管事件（MACE：心血管死亡、非致死性心肌梗死、非致死性卒中）风险显著降低26%[6]。这一心血管获益，正是其“一石三鸟”协同效应在临床终点上的集中体现。对SUSTAIN 1~7研究的事后分析发现，与安慰剂治疗相比，司美格鲁肽治疗能持续降低2型糖尿病患者的蛋白尿水平，合并微量和大量白蛋白尿的患者蛋白尿水平降幅最大（达约50%）[15]。其中，SUSTAIN 6研究已证实司美格鲁肽可进一步改善肾脏结局，对次要肾脏终点事件的分析发现，司美格鲁肽能有效延缓具有心血管高风险的2型糖尿病患者糖尿病肾脏病的发生和发展，使肾脏复合终点事件发生风险降低36%[6]。结语司美格鲁肽为困扰临床多年的三高共管难题提供了有力的“破局”利器。它打破了传统“分项治疗、多药叠加”的固有模式，实现“单一路径，多重获益”，通过降低体重、改善胰岛素抵抗、促进排钠、调节脂代谢、抗炎和保护血管等多重交织的机制，实现了对高血糖、高血压、血脂异常三大危险因素高效协同的“一石三鸟”式干预。这是治疗策略的跃升——从传统的“叠加用药”模式迈向高效的“协同管理”策略，不仅简化了治疗方案，提高了患者的依从性和治疗效率，更标志着代谢性疾病管理迈入了追求“多重危险因素协同控制、改善长期硬终点”的新时代。对于广大合并多重代谢风险的2型糖尿病患者而言，司美格鲁肽代表了一种更为高效、综合且具有深远健康意义的治疗新选择。刘亚辉主治医师保定市高阳县第三医院（邢家南镇卫生院）内科主任河北省基层卫生协会糖尿病与肥胖健康管理专业委员会委员从事临床工作20余年。专业特长：糖尿病及急慢性并发症的诊断治疗，甲状腺功能亢进及减退，高血压、冠心病等慢性病的诊断及预防。参考文献（上下滑动可查看） 1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. 2. V R Aroda, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019 Oct;45(5):409-418. 3. Silvia Patricia Alonso, et al. GLP-1 agonists in glycemic and weight control of type 2 diabetes. New perspectives. Med Clin (Barc). 2025 Sep;165(3):107042. 4. Andrew J Ahmann, et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018 Feb;41(2):258-266. 5. Linong Ji, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021 Feb;23(2):404-414. 6. Steven P Marso, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. 7. Helena W Rodbard, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. J Clin Endocrinol Metab. 2018 Jun 1;103(6):2291-2301. 8. Andrej Belanciˇ，et al. Blood pressure effects of SGLT2 inhibitors and GLP-1 receptor agonists: Mechanisms, trial evidence and Real-world data. Br J Clin Pharmacol. 2025 Dec 4. doi: 10.1002/bcp.70378. Online ahead of print. 9. Areesha Moiz, et al. GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications. Am J Hypertens. 2025 Oct 23:hpaf205. doi: 10.1093/ajh/hpaf205. Online ahead of print. 10. Momina A Allahwala, et al. Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond. Heart Lung Circ. 2025 Oct;34(10):995-1005. doi: 10.1016/j.hlc.2025.07.005. 11. Ushna Gul, et al. A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure. Cureus. 2024 Dec 28;16(12):e76519. doi: 10.7759/cureus.76519. eCollection 2024 Dec. 12. Francesco Piccirillo, et al.Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets. Int J Mol Sci. 2023 Jun 15;24(12):10164. doi: 10.3390/ijms241210164. 13. Patel V, Joharapurkar A, Kshirsagar S, et al.: Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition. Chem Biol Interact. 2018, 282:13-21. 14. Linong Ji, et al. Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China. Diabetes Obes Metab. 2024 Jan;26(1):233-241. 15. Mann J, Hansen T, Idorn T, et al. Effects of once‐weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post‐hoc analysis of the SUSTAIN 1‐7 randomised controlled trials[J]. Lancet Diabetes Endocrinol, 2020, 8(11):880‐893. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

2025-12-11

·BioPharmaDive

Prolynx banks $70M for longer-lasting obesity drugs

Biotechnology startup Prolynxhas raised $70 million in Series A funding that will support plans to develop obesity drugs that require less frequent dosing than existing medications.Announced Thursday, the Emeryville, California-based startups financing was led by 5AM Ventures, OrbiMed and Monograph Capital. The company will use that cash to advance a portfolio of longer-acting incretin drugs which stimulate or mimic the effects of certain gut hormones as well as non-incretin therapies, according to CEO Chris Boulton.Boultoun described the biotechs portfolio as potential solutions for a disease, obesity, that is not just one condition, but multiple conditions. That view is reflected by the opportunity drugmakers still see in making new obesity medicines, despite the dominance of two effective and widely used therapies, Eli Lillys Zepbound and Novo Nordisks Wegovy.Those drugs spur significant weight loss, but also require weekly injections and are associated with certain gastrointestinal side effects that can lead people to stop treatment. Many drugmakers are tinkering with new variationsthat might be more potent, convenient, tolerable or dosed less frequently, increasing the likelihood that a patient stays on treatment.The potential reward is substantial. Combined sales this year of Lillys Zepbound and Mounjaro a diabetes drug that shares Zepbounds same active ingredient have made it the worlds most lucrative medicine. Some analysts expectthe market for Zepbound and other drugs like it to surpass $100 billion by 2030.That opportunity has spurred dealmaking by large pharmaceutical companies and investments by venture capitalists. Each of the last two years, venture firms have poured at least $1 billion into startups working on metabolic disease drugs, according to BioPharma Dive data.Chris Boulton, a veteran of Amgen and Sanofi, joined Prolynx as its CEO in November 2025.Permission granted by ProlynxProlynx aims to stand out by focusing on drugs that can be dosed as infrequently as once monthly or quarterly.Its leaning on a type of extended-release technology Prolynx originally targeted for usein cancer when the company was launched more than a decade ago by founders Daniel Santi and Gary Ashley.According to Boulton, the companys technology involves proprietary chemical linkers that bind a drug to a carrier molecule and enables a controlled, predictable and sustained release of that therapy. One way Prolynx will use it is to make a version of semaglutide, the active ingredient in Novos Wegovy, thats administered once monthly.If you can find treatments that last a little bit longer, you can smooth out those peaks and troughs and minimize some dose-related side effects, Boulton said.Boulton said the company intends to make use of a regulatory pathwaythat enables drugmakers to bring to market modified versions of existing medicines more quickly, in part, by borrowing from existing data.Behind a longer-acting semaglutide are formulations of a dual-acting GLP-1/GIPR agonist and an amylin drug both well-studied obesity targets that could be dosed monthly or quarterly. The company didnt disclose when it expects to get its experimental medicines into clinical testing.Boulton, who has worked in obesity or metabolic drug roles at Amgen, Sanofi and AstraZeneca, joined Prolynx in November.Working at big companies, you know what good looks like, he said. You know where the bar is and you can aim for that. '

100 项与司美格鲁肽(宜昌人福药业) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A10BJ06	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床1期	中国	海南双成药业股份有限公司	2024-11-29
2型糖尿病	临床1期	中国	宜昌人福药业有限责任公司	2024-11-29